Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 80Recurrence 17Neoplasms, Plasma Cell 9Immunoglobulin Light-chain Amyloidosis 9Neoplasms 4Lymphoma, Large B-Cell, Diffuse 4Amyloidosis 3Waldenstrom Macroglobulinemia 2Polycythemia Vera 2Paraproteinemias 2Myeloproliferative Disorders 2Lymphoma, B-Cell 2Hematologic Diseases 2Chromosome 17 deletion 2Burkitt Lymphoma 2Blood Protein Disorders 2Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytosis 1Thrombocythemia, Essential 1Smoldering Multiple Myeloma 1Renal Insufficiency 1Proteostasis Deficiencies 1Primary Myelofibrosis 1Plasmacytoma 1Pancreatic Neoplasms 1Neoplasms by Histologic Type 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Plasma Cell 1

Interventions

Dexamethasone 4Methods 2Electroencephalography 2selinexor 1pomalidomide 1ixazomib 1Transurethral Resection of Bladder 1Telemedicine 1Tablets 1Surgical Procedures, Operative 1Standard of Care 1Neurofeedback 1Melphalan 1Mass Screening 1Magnetic Resonance Imaging 1Lysine Acetyltransferase 5 1Hypnosis 1Hormones 1Exercise 1Ethanol 1Drug Delivery Systems 1Cyclophosphamide 1Control Groups 1Cholinesterase Inhibitors 1Calcium Dobesilate 1Bortezomib 1Biopsy 1Amyloid 1Amputation, Surgical 17-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Alzheimer Disease × pomalidomide × Clear all
NCT04270175 2026-02-27

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Weill Medical College of Cornell University

Phase 2 Active not recruiting
15 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡